As we pass the halfway point of 2025, our latest report offers a deep dive into the key market dynamics, M&A trends, and evolving leadership demands shaping the sector. 

This report provides critical insights into the shift towards complex products, the growing influence of private equity, and the essential leadership qualities needed to thrive in the generics and biosimilars industry. 

Download your copy today to understand the strategic recalibration underway and prepare your organisation for the anticipated surge in H2 2025 hiring.